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Objectives: To estimate the procedure-related risks of miscarriage after amniocentesis 36 
and trans-abdominal chorionic villus sampling (CVS) based on a systematic review of 37 
the literature and an updated meta-analysis. 38 
Methods: A search of MEDLINE, EMBASE, and The Cochrane Library was carried out 39 
to identify studies reporting complications following CVS or amniocentesis. The inclusion 40 
criteria for the systematic review were studies reporting results from large controlled 41 
studies and those reporting data for pregnancy loss prior to 24 weeks’ gestation. Study 42 
authors were contacted when required to identify additional necessary data. Data for 43 
cases that had invasive procedure and controls groups were inputted in contingency 44 
tables and risk of miscarriage was estimated for each study. Summary statistics based 45 
on a fixed and random effects model were calculated after taking into account the 46 
weighting for each study included in the systematic review. Procedure-related risk of 47 
miscarriage was estimated as a weighted risk difference from the summary statistics for 48 
cases and controls. A subgroup analyses according to the similarity risk levels in the 49 
invasive testing and control groups was performed. Heterogeneity was assessed using 50 
Cochrane’s Q and I2 statistic. Egger Bias was estimated to assess reporting bias in 51 
published studies. Summary statistics for procedure-related risk of miscarriage were 52 
graphically represented in Forest plots. 53 
Results: The electronic search from the databases yielded 2,943 potential citations, from 54 
which, we selected 20 controlled studies for inclusion in the systematic review to estimate 55 
the procedure-related risk of miscarriage from invasive procedures. There were a total 56 
of 580 miscarriages from 63,273 amniocentesis procedures with a weighted risk of 57 
pregnancy loss of 0.91% (95%CI: 0.73 to 1.09). In the control group, there were 1,726 58 
miscarriages in 330,469 pregnancies with a loss rate of 0.58% (95CI%: 0.47 to 0.70). 59 
The weighted procedure-related risk of miscarriage was 0.30% (95%CI: 0.11 to 0.49, 60 
I2=70.1%). There were a total of 163 miscarriages from 13,011 CVS procedures with a 61 
risk of pregnancy loss of 1.39% (95%CI: 0.76 to 2.02). In the control group, there were 62 
1,946 miscarriages in 232,680 pregnancies with a loss rate of 1.23% (95CI%: 0.86 to 63 
1.59). The weighted procedure-related risk of miscarriage following CVS was 0.20% 64 
(95%CI: -0.12 to 0.52, I2=51.9%). However, when only studies with similar risk profiles 65 
between the intervention and control groups were considered, the procedure related risk 66 
for amniocentesis became 0.03% (95%CI -0.08 to 0.14, I2=0%) and for CVS -0.38 (95% 67 
CI -1.12 to 0.36, I2=0%). 68 
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Conclusion: The procedure-related risks of miscarriage following amniocentesis and 69 
CVS are lower than currently quoted to women. The risk appears to be negligible when 70 






There is considerable evidence suggesting that the procedure-related risks of 75 
miscarriage following amniocentesis and chorionic villus sampling (CVS) are much lower 76 
than are currently quoted by professional bodies.1-3 The pooled summary statistics of 77 
these procedure-related risks based on data reported in large controlled cohort studies 78 
published until January 2014 were reported in a systematic review and meta-analysis.4,5 79 
There have been further large studies published in the last few years reporting the 80 
procedure-related risks of miscarriage following invasive procedures from large cohort, 81 
population and randomised controlled studies with data from more than 20,000 82 
procedures.6-11 We aimed to derive updated procedure-related risks of miscarriage after 83 
including data from all studies published till 31st January 2019 in order to provide 84 





Eligibility criteria 90 
The articles eligible for inclusion in our study were randomised controlled trials, 91 
prospective or retrospective cohort or case-control studies reporting on the pregnancy 92 
outcomes in women who had invasive prenatal testing and that of control pregnancies 93 
that did not have an invasive procedure. In view of the improvements and advances in 94 
ultrasound resolution and the subsequent improvements in the techniques of performing 95 
CVS/amniocentesis over the last couple of decades, we only included studies published 96 
from year 2000 onwards to ensure uniformity in comparing results of studies using similar 97 
equipment and techniques. In case of studies reporting data spanning years before and 98 
after 2000, we only included cases that underwent invasive testing from 2000 onwards. 99 
We only included studies reporting their data in English language.  100 
Types of participants: We included studies reporting their data on invasive procedures 101 
carried out in singleton pregnancies. Studies reporting results from both singleton and 102 
multiple pregnancies were deemed eligible if data from multiple pregnancies were <5% 103 
of the total sample size. 104 
Types of interventions: We compared women who underwent invasive prenatal testing 105 
(CVS or amniocentesis) to those that did not have any invasive procedure. When 106 
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separate data were reported for transabdominal and transcervical CVS, only the former 107 
group was entered in the analyses. 108 
Outcome measures: Miscarriage, defined as fetal loss before 24 or 22 weeks12. In 109 
studies reporting data for miscarriage due to various causes, we only included 110 
procedure-related losses, i.e. those not associated with structural anomalies or other 111 
factors likely to cause miscarriage independently from invasive testing. 112 
  113 
Data sources and search strategy 114 
This systematic review and meta-analysis was undertaken based on an a-priori designed 115 
study protocol and was registered in advance with the PROSPERO International 116 
Prospective Register of Systematic Reviews (Registration number: CRD42019130495). 117 
An electronic search of MEDLINE, EMBASE, and The Cochrane Library was carried out 118 
on 31st January 2019 utilising combinations of the relevant Medical Subject Heading 119 
(MeSH) terms, key words, and word variants for “Amniocentesis”,” Chorionic Villus 120 
Sampling (CVS)”, “miscarriage”, “pregnancy loss” and “procedure-related risk”. The 121 
search and selection criteria were restricted to studies reported in English language. The 122 
citations retrieved following this search strategy were examined for relevance to this 123 
study based on the type of invasive prenatal procedure, study design, sample size of the 124 
study, study period and gestational age at assessing pregnancy outcome. We 125 
complemented the searches by perusing the references of retrieved articles and the 126 
studies included in previous systematic reviews on the topic. 127 
 128 
Study selection and data extraction 129 
Search results were screened by two of the authors (RA and LJS) and the full text of all 130 
relevant studies was reviewed. The citations were examined to produce a list of relevant 131 
studies after excluding studies that were duplicates, those that did not fit selection criteria 132 
after review of title and abstract and those that were case-reports, letters, or review 133 
articles. These two authors independently assessed for inclusion all the potential studies 134 
identified from the search strategy. Data were extracted using a pre-specified form. We 135 
resolved any disagreement through discussion or, if required, we consulted a third author 136 
(AS). 137 
 138 
For each study, we recorded information about the authors, country of origin, years of 139 
enrolment for the intervention and control groups, indications for invasive testing, 140 
technique of CVS/amniocentesis, experience of the operators, characteristics of control 141 
6 
 
women and risk level for the two groups. We recorded the number of terminations of 142 
pregnancy and we subtracted these cases from the denominator. We contacted the 143 
authors of primary study if further details or clarifications were required. 144 
 145 
Risk of bias of individual studies  146 
The methodological quality of studies included in the systematic review was assessed 147 
using the Newcastle-Ottawa Scale (NOS)13. Briefly, NOS assess the quality of cohort or 148 
case-control studies across three domains, i.e. selection (including representativeness 149 
of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure 150 
and demonstration that the outcome of interest was not already present at the start of 151 
the study), comparability and outcome (including assessment of outcome and adequacy 152 
of follow-up length). The assessment of the domains is performed based on a 153 
standardized checklist and indicators of high quality are awarded a star; the number and 154 
combination of stars expresses the overall quality of a study in an AHRQ-compliant way 155 
(good, fair or poor).  156 
 157 
We reported our study as per PRISMA (Preferred Reporting Items for Systematic reviews 158 
and Meta-Analyses) (Supplementary Table 1).14 159 
 160 
Summary measures and synthesis of the results 161 
The data from each study was extracted to note the type of procedure, study design, 162 
sample size, and miscarriage rate in each study group. Study authors were contacted 163 
when required to identify additional necessary data. Data were entered in contingency 164 
tables and miscarriage rate (95% confidence interval [CI) was estimated in the invasive 165 
procedure and the control group, for each study as well as a pooled estimate, weighted 166 
by sample size of each study. The procedure-related risk for amniocentesis and CVS for 167 
each study were estimated as a risk difference (RD) based on the miscarriage rates in 168 
the invasive and control group, which were then used to calculate the weighted pooled 169 
summary estimate (95% CI). Given the non-randomized design and the anticipated 170 
heterogeneity of the studies, we calculated the summary effect sizes using random 171 
effects models. The random effects model assumes that the true effect size varies 172 
between the studies, and that included studies represent a random sample of effect sizes 173 
that could have been observed. Therefore, we opted to use this model as it allows for 174 
not just for variation within studies but also variation between studies, thus providing a 175 
conservative estimate of the summary statistics with wider CIs.15 The procedure-related 176 
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risks for amniocentesis and CVS were graphically expressed in Forest plots. Pooled 177 
proportions were calculated using the metaprop command. The heterogeneity between 178 
studies was assessed by estimation of Cochrane’s Q and I2 statistic; Egger’s meta-179 
regression test was used to assess reporting bias in studies when 10 or more studies 180 
were available.16-18  181 
 182 
Subgroup analyses 183 
We planned subgroup analyses according to the similarity risk levels in the invasive 184 
testing and control groups, as extracted by their description in the primary studies (similar 185 
or dissimilar risk), as this could be related to confounders that can affect the procedure-186 
related risk, and therefore the risk difference (RD).  187 
 188 
We carried out statistical analyses in Stata 14.0 software (StataCorp College Station, 189 





Data search results 195 
The electronic search from the databases yielded 2,943 potential citations of which 2,907 196 
were excluded as they were duplicates, or a review of the title or abstract did not meet 197 
the inclusion criteria, leaving 36 studies for full-text review. After the full manuscript 198 
review, we finally considered 12 studies for amniocentesis6,7,9-11,19-25 and 8 studies for 199 
CVS6-8,10,11,26-28 Of those, one study (Lau et al., 2005) was eventually excluded26, as it 200 
gave cumulative data for miscarriage and stillbirth, leaving 12 studies for amniocentesis 201 
and 7 for CVS. The raw data for the Wulff et al., 20166 study were calculated from the 202 
published adjusted estimates and were complemented with additional information 203 
provided by the authors. Similarly, the authors of Malan et al., 2018 were contacted to 204 
obtain data additional data for amniocentesis and CVS.10 The characteristics of the 205 
included studies are shown in Supplementary Table 2. 206 
 207 
Assessment of the quality of included studies 208 
The methodological quality of studies was assessed using the NOS. The rating of the 209 
included studies according to the NOS based on study type, selection, comparability and 210 




Amniocentesis group 213 
There were a total of 580 miscarriages from 63,723 amniocentesis procedures with a 214 
pooled risk of pregnancy loss of 0.91% (95%CI 0.73 to 1.09, I2=88.2%). In the control 215 
group, there were 1726 miscarriages in 330469 pregnancies with a pooled loss rate of 216 
0.58% (95%CI 0.47 to 0.70, I2=96.1%). The pooled procedure-related risk of miscarriage 217 
was 0.30% (95%CI: 0.11 to 0.49), I2=70.1% (Figure 2).  218 
 219 
Chorionic villus sampling group 220 
There were a total of 163 miscarriages from 13,011 CVS procedures, with a pooled risk 221 
of pregnancy loss of 1.39% (95%CI 0.76 to 2.02, I2=89.1%). In the control group, there 222 
were 1,946 miscarriages in 232,680 pregnancies with a pooled loss rate of 1.23% 223 
(95%CI 0.86 to 1.59, I2=98.1%). The pooled procedure-related risk of miscarriage 224 
following CVS was non-significant (0.20, 95%CI: -0.12 to 0.52, I2=51.9%) (Figure 3). 225 
 226 
Subgroup analyses 227 
For each invasive test (amniocentesis or CVS) we examined the procedure-related risk 228 
of miscarriage separately for studies with similar or dissimilar risk level for chromosomal 229 
abnormalities. The pooled risk RD (i.e. procedure related risk) for amniocentesis was 230 
0.46% (95%CI 0.25 to 0.67, I2=38.1%) when studies with dissimilar risk level for the two 231 
groups were synthesized. When studies with similar risk levels for the amniocentesis and 232 
control groups were synthesized, there was no significant procedure-related risk (RD 233 
0.12 95%CI -0.05 to 0.30%, I2=44.1%) (Figure 4). 234 
 235 
The procedure-related risk for CVS was non-significant when studies with similar level 236 
of risk between the two groups were compared (pooled RD -0.011, 95%CI -0.29 to 0.08, 237 
I2=0%). In contrast, CVS was associated with a pooled prodedure-related risk of 0.48% 238 
(95%CI 0.17 to 0.78, I2=0%) when studies with dissimilar level of risk between the 239 
intervention and control group were synthesized (Figure 5). 240 
 241 
Publication bias 242 
We were able to assess the potential for publication bias for amniocentesis only, as the 243 
number of CVS studies was less than 10. The Egger’s meta-regression test did not 244 







Main findings 250 
The results of our study demonstrate the following facts: first, the procedure-related risk 251 
of miscarriage is considerably lower than is currently quoted in guidelines from 252 
professional bodies and is 0.30% following amniocentesis, whereas there is no 253 
significant procedure-related risk associated with CVS, which may be a safer procedure 254 
than amniocentesis;; second, our results highlight that the point-estimates for 255 
miscarriage are even substantially lower with no significant increase in risk of miscarriage 256 
for both, amniocentesis and CVS, when the analysis is restricted to studies in which the 257 
control population has a similar risk profile for chromosomal abnormalities as the women 258 
who underwent invasive prenatal testing.  259 
 260 
Strengths and limitations 261 
This is an updated version of our previous meta-analyses, adding the only new 262 
randomized trial10 in three decades and following a new approach to address the issue 263 
of heterogeneity between reported studies.   264 
 265 
The published studies have used different indications for invasive testing and different 266 
selection criteria for the control women, culminating in different background risk levels 267 
for the compared groups both within and across studies. The resulting heterogeneity has 268 
been the major argument against quantitative synthesis of such studies. To this end, we 269 
have taken the following measures. First, we excluded terminations of pregnancy from 270 
both the intervention and control groups. Second, we excluded cases of miscarriage 271 
directly attributable to structural defects or obstetric complications unrelated to invasive 272 
testing, if data were available. Third, we only analysed invasive procedures performed 273 
from 2000 onwards, if such data were available, to account for the progress in ultrasound 274 
resolution and sampling techniques. Fourth, we stratified the intervention and control 275 
groups according to their risk profiles, as extracted from their inclusion criteria, and we 276 
separately analysed studies where the two groups had similar risk profiles. This analysis 277 
highlighted the impact of dissimilar background risks as a source of risk inflation and 278 
statistical heterogeneity. Fifth, anticipating that the studies do not represent random 279 
samples from the same population, we used the random effects model, which does not 280 
assume a common underlying effect size and produces more conservative estimates. In 281 
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any case, as the control groups have usually more favourable risk profile, any bias would 282 
be against invasive procedures, which means that the latter may be even safer than they 283 
appear in an aggregate analysis. 284 
 285 
There are some limitations to our study which could not be overcome despite our robust 286 
methodology of well-defined eligibility criteria, inclusion of controlled studies with large 287 
sample size, as well as the strict approach to minimising heterogeneity. A limitation of 288 
our study is that when we compared the risks of miscarriage in the intervention and 289 
control pregnancies with similar risk profile and background risks, these were mainly in 290 
high-risk populations and the results of our study therefore cannot comment on risk 291 
estimates of miscarriage, if these were performed in large low-risk populations. In our 292 
study, we did not examine other pregnancy complications such as preterm birth and 293 
stillbirth nor did we examine the serious but rare outcomes such as maternal septicaemia 294 
or amniotic fluid embolism as they were not consistently reported by included studies. 295 
Another limitation refers to lack of analyses of data with regard to operator experience 296 
as it is potentially an important factor associated with procedure-related loss. 297 
Unfortunately, with the exception of two recent studies with conflicting results (Akolekar 298 
et al., 2011 and Bakker et al., 2017)7,27, the rest of the studies do not provide data about 299 
the effect of operator experience on the risk of miscarriage, and we were unable to 300 
account for this in our analyses.  301 
 302 
Interpretation of the findings 303 
The first question we aimed to address is whether invasive prenatal diagnosis is a safe 304 
procedure. Our results suggest that amniocentesis is associated with a procedure-305 
related risk of 1:300 at most, or more likely, no significant increase in risk if we considered 306 
the results from our analysis which only included studies with comparable risk profile in 307 
the intervention and control groups. With regard to CVS, our results demonstrate that, 308 
there is no significant procedure-related risk associated with undertaking this procedure.  309 
  310 
A second, related question is whether, which is a safer procedure to undertake, CVS or 311 
amniocentesis. There is no statistically appropriate way to answer this through either a 312 
direct or network meta-analysis, as the two methods do not have a common comparator. 313 
The closest approximation to a valid answer to this question is to estimate a pooled 314 
procedure-related risk from those studies which reported results for both amniocentesis 315 
and CVS by comparison with a control group. There were four such studies (Wulff et al., 316 
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2016, Bakker et al.,2017, Malan et al.,2018 and Beta et al., 2019)6,7,10,11 comparing both 317 
CVS and amniocentesis to their corresponding control groups; their pooled procedure-318 
related risk was 0.11% (95%CI -0.28 to 0.50, I2=42.1%) for CVS and 0.55% (95%CI 0.29 319 
to 0.81, I2=0%) for amniocentesis. There are a few hypotheses than can potentially 320 
explain the reasons for these differences and the apparent greater safety of CVS 321 
compared to amniocentesis. Firstly, CVS is usually performed by specialist and 322 
experienced Fetal Medicine operators compared to amniocentesis; secondly, performing 323 
a CVS involves introduction of the needle into the placental tissue, which is highly 324 
vascular tissue with blood flow of about 90-100 mL/minute/kg at 12 weeks’ gestation29,30, 325 
as opposed to introduction of a needle into the amniotic sac, which is a closed cavity and 326 
therefore has a higher chance of a potential infection introduced into a confined 327 
intraamniotic space and lastly, the option to reschedule the procedure and undertake 328 
amniocentesis if there are technical limitations.  329 
 330 
The quest to accurately quantify procedure-related risks for invasive procedures may 331 
seem trivial. However, we consider it to be quite important and relevant to current clinical 332 
practice. There is a recent systematic review in 2017 attempting to quantify procedure-333 
related risks of miscarriage from published RCTs with the conclusion that second 334 
trimester amniocentesis increases the risk of procedure-related loss but it is not possible 335 
to quantify this increase precisely from one study.31 Such conclusions are unhelpful and 336 
do not provide the women nor their clinicians any clear evidence-based estimates of risks 337 
for decision making. These invasive procedures are still routinely carried out for prenatal 338 
diagnosis but instead of accurate and recent estimates of risks from expert operators, 339 
these are rather based on historical and inflated estimates of risks. There are significant 340 
advances in cytogenetics analysis and genomic sequencing which are progressing at a 341 
rapid pace, and pregnant women must receive appropriate counselling to enable them 342 
to make informed choices about their options for prenatal testing, without being deterred  343 
by falsely exaggerated rates of procedure-related risks of miscarriage. Until such a time 344 
that  non-invasive testing is not diagnostic and as comprehensive as cytogenetics 345 
techniques, the questions about the safety of invasive procedures and the factors 346 
affecting it remain topical.32 347 
 348 
Comparison with previous studies 349 
In comparison to our previous meta-analyses4,5, this update includes the first RCT 350 
published in the last three decades and it addresses the issue of heterogeneity by 351 
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carefully excluding cases potentially affected by confounders and by accounting for the 352 
effect of different background risks. In terms of numerical estimates, the procedure 353 
related risk of amniocentesis seems to stabilize around 1:300, whereas the risk 354 
difference between CVS and controls still fails to reach significance. The most important 355 
novelty is the synthesis of studies in which the intervention and control groups had similar 356 
background risks for chromosomal abnormalities, as derived from their description. It 357 
appears that, when comparing women at a similar risk level (be it high, intermediate or 358 
low, Table 1), the procedure-related risk for amniocentesis also fails to reach 359 
significance, whereas the statistical heterogeneity substantially decreases. This is a 360 
significant finding, supporting the concept that, all other things being equal, an invasive 361 
procedure is not associated with a significant increase in the rate of miscarriage. This 362 
does not imply that a miscarriage following an invasive procedure cannot occur, but this 363 
is more likely to be related to either operator-independent maternal factors (Akolekar et 364 
al., 2011)27, or to the experience and technique of the operator, rather than the procedure 365 
itself. In a large UK study, the authors reported that there was no significant increase in 366 
overall procedural risk of miscarriage, regardless of whether the procedure was carried 367 
out by fetal medicine experts or trainees under direct supervision of an expert (Akolekar 368 
et al., 2011), whereas the point estimates of procedure-related miscarriage appeared to 369 
decrease with operators’ experience, though in a non-significant way in a Dutch study 370 
(Bakker et al., 2017).7,27 As neither of these studies were randomised, there is no reliable 371 
way to ascertain how experience may impact on outcomes or the effects are subject to 372 
modifications by confounders like negative selection bias. 373 
 374 
In terms of raw numbers and sample size of studies, the evidence is dominated by a 375 
large Danish registry study, which shows that invasive procedures themselves do not 376 
carry a significant miscarriage risk (Wulff et al., 2017).6 The random effects model we 377 
used reduces the weight (and therefore the dominance) of this single trial, which in any 378 
case is in line with the aggregate findings. Similarly, the French multicentre RCT, which 379 
aimed to show that there would be a reduction in the risk of miscarriage in the group that 380 
was offered invasive testing only for positive cfDNA results (n=1,034) as opposed to 381 
those with direct invasive testing (n=1,017), also failed to show a significant difference 382 





The results of this systematic review and meta-analysis demonstrate that the procedure-386 
related risks of miscarriage from invasive procedures are low, or negligible if groups with 387 
similar background risks are compared. In terms of safety of a prenatal diagnostic 388 
procedure, it appears that CVS is potentially safer compared to amniocentesis. Women 389 
should be reassured that invasive procedures carried out by experienced operators in 390 
specialist centres are not associated with a significant increase in miscarriage rate as 391 
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Figure legends  496 
 497 
Figure 1. Flowchart of study selection of studies included in the meta-analysis. 498 
Figure 2. Procedure-related risk for miscarriage after amniocentesis, expressed as risk 499 
difference (RD, 95% CI) to controls (Random effects model) 500 
Figure 3. Procedure-related risk for miscarriage after chorionic villus sampling (CVS), 501 
expressed as risk difference (RD, 95% CI) to controls (Random effects model) 502 
Figure 4. Subgroup analysis for the procedure-related risk of miscarriage after 503 
amniocentesis, expressed as risk difference (RD, 95% CI) to controls (Random effects 504 
model). Subgroup 1 included studies in which the intervention and control groups had 505 
similar risk profile (i.e. they were both of high-, intermediate- or low risk). Subgroup 2 506 
included studies in which the intervention and control groups had similar risk profile 507 
Figure 5. Subgroup analysis for the procedure-related risk of miscarriage after 508 
amniocentesis, expressed as risk difference (RD, 95% CI) to controls (Random effects 509 
model). Subgroup 1 included studies in which the intervention and control groups had 510 
similar risk profile. Subgroup 2 included studies in which the intervention and control 511 
groups had similar risk profile (i.e. they were both of high-, intermediate- or low risk). 512 
Supplemental figure. Egger’s meta-regression test for the presence of small-study 513 
effects. 514 
